EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world effectiveness and safety of enavogliflozin in patients with type 2 diabetes: A 24‐week prospective multicenter observational study in Korea

Hyunji Sang iD, Yeongtaek Hwang, Selin Woo iD, Soo Jin Yun iD, Meehoh Kim iD, Ho Geol Woo, Joo Young Kim, Dong Keon Yon iD, Sang Youl Rhee iD

Journal of Diabetes Investigation · 28.10.2026

DOI: 10.1111/jdi.70478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 28.10.2026. Verfasst von Hyunji Sang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction To evaluate the real‐world effectiveness and safety of enavogliflozin as a single‐pill formulation (Enavo group; enavogliflozin 0.3 mg) or fixed‐dose combination with metformin (EnavoMet group; enavogliflozin 0.3 mg/metformin 1000 mg) in patients with type 2 diabetes (T2DM) in Korean primary care. Materials and Methods This prospective, multicenter, non‐interventional observational study enrolled 8796 adults with type 2 diabetes mellitus from 273 primary care clinics across Korea (Safety Set). The full analysis set comprised 8704 participants (Enavo: 7046; EnavoMet: 1658) with baseline and at least one post‐baseline glycated hemoglobin (HbA1c) measurement. The primary endpoint was HbA1c change at 24 weeks. Results At 24 weeks, mean HbA1c decreased by −0.69 percentage points (95% CI: −0.71, −0.67) in Enavo ( n = 7003) and −0.86 (−0.90, −0.82) in EnavoMet ( n = 1648). In these paired cohorts, 1728 (24.7%) and 371 (22.5%), respectively, already had HbA1c

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitorenavogliflozinreal‐world evidence

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Department of Neurology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Gangnam Endo Clinic, Seoul, South Korea.
  • Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.

ORCID-Profile: Hyunji Sang, Selin Woo, Soo Jin Yun, Meehoh Kim, Dong Keon Yon, Sang Youl Rhee

Zitieren

APA

Sang, H., Hwang, Y., Woo, S., Yun, S. J., Kim, M., Woo, H. G., Kim, J. Y., Yon, D. K., & Rhee, S. Y. (2026). Real‐world effectiveness and safety of enavogliflozin in patients with type 2 diabetes: A 24‐week prospective multicenter observational study in Korea. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70478

Vancouver

Sang H, Hwang Y, Woo S, Yun SJ, Kim M, Woo HG, et al. Real‐world effectiveness and safety of enavogliflozin in patients with type 2 diabetes: A 24‐week prospective multicenter observational study in Korea. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70478

BibTeX
@article{Sang2026,
  author = {Sang, Hyunji and Hwang, Yeongtaek and Woo, Selin and Yun, Soo Jin and Kim, Meehoh and Woo, Ho Geol and Kim, Joo Young and Yon, Dong Keon and Rhee, Sang Youl},
  title = {Real‐world effectiveness and safety of enavogliflozin in patients with type 2 diabetes: A 24‐week prospective multicenter observational study in Korea},
  journal = {Journal of Diabetes Investigation},
  year = {2026},
  doi = {10.1111/jdi.70478}
}
Kostenlos starten →